Article

Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.

Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, B-3000 Leuven, Belgium.
Oncology Reports (Impact Factor: 2.19). 04/2008; 19(4):927-32. DOI: 10.3892/or.19.4.927
Source: PubMed

ABSTRACT In this proof-of-principle study, the necrosis avid agent hypericin was investigated as a potential indicator for early therapeutic response following radiofrequency ablation (RFA) of murine liver tumors. Eight mice bearing intrahepatic RIF-1 tumors were intravenously injected with hypericin 1 h before or 24 h after RFA treatment. Mice were euthanized 24 h after hypericin injection and excised livers were investigated by means of fluoromacroscopic and fluoromicroscopic examinations in combination with conventional histomorphology. Significant differences in hypericin fluorescence were found in necrosis, viable tumor and normal liver tissue in a decreasing order: in necrosis, mean fluorescence densities were about 5 times higher than in viable tumor and approximately 12 times higher than in normal liver (p<0.05). Mean fluorescence densities were not significantly different when hypericin was injected 24 h after or 1 h before RFA treatment (p>0.05). As a conclusion, hypericin features the property to specifically enhance the imaging contrast between necrotic and viable tissues and to non-specifically distinguish viable tumor from normal liver. The results suggest that hypericin offers significant potential in the early assessment of response following necrosis-inducing antineoplastic treatments such as RFA.

1 Follower
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Following the footprint of porphyrin-mediated photodynamic therapy (PDT), paramagnetic metalloporphyrins were originated as tumor seeking contrast agents (CAs) for magnetic resonance imaging (MRI). However, serial research has disproved their tumor selectivity, identified nonviable tissues as their real targets, and eventually elicited new applica-tions in myocardial infarction delineation, tissue viability evaluation, ablation therapy assessment, as well as first pass or dynamic perfusion MRI, multi-organ contrast enhancement (CE), atherosclerotic plaque imaging and stem cell labeling or tracking. Furthermore, nonporphyrin analogues have been developed to reduce porphyrin related toxicities. These porphy-rin and nonporphyrin compounds have been termed as necrosis-avid contrast agents (NACAs) to denote their major dis-covered affinity. The present review aims to document the evolving research in this particular field, to discuss possible mechanisms, to promote further preclinical and clinical development of this unique and promising class of MRI CAs, and to implicate a novel stroma targeting strategy for diagnosis and treatment of malignant and benign disorders.
    Current Medical Imaging Reviews 05/2008; 4(2). DOI:10.2174/157340508784356789 · 1.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We sought to establish and characterize a mouse liver tumor model as a platform for preclinical assessment of new diagnostics and therapeutics. Radiation-induced fibrosarcoma (RIF-1) was intrahepatically implanted in 27 C3H/Km mice. Serial in vivo magnetic resonance imaging (MRI) with a clinical 1.5-T-magnet was performed using T1- (T1WI), T2- (T2WI), and diffusion-weighted sequences (DWI), dynamic contrast-enhanced MRI (DCE-MRI), and contrast-enhanced T1WI, and validated with postmortem microangiography and histopathology. Implantation procedure succeeded in 25 mice with 2 deaths from overdosed anesthesia or hypothermia. RIF-1 grew in 21 mice with volume doubling time of 2.55+/-0.88 days and final size of 216.2+/-150.4 mm(3) at day 14. Three mice were found without tumor growth and one only with abdominal seeding. The intrahepatic RIF-1 was hypervascularized with negligible necrosis as shown on MRI, microangiography and histology. On DCE-MRI, maximal initial slope of contrast-time curve and volume transfer constant per unit volume of tissue, K, differed between the tumor and liver with only the former significantly lower in the tumor than in the liver (P<0.05). Liver implantation of RIF-1 in mice proves a feasible and reproducible model and appears promising for use to screen new diagnostics and therapeutics under noninvasive monitoring even with a clinical MRI system.
    European Radiology 07/2008; 18(7):1422-30. DOI:10.1007/s00330-008-0904-2 · 4.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the widespread use of various imaging modalities in clinical and experimental oncology without or with combined application of commercially available nonspecific contrast agents (CAs), development of tissue- or organ- or disease-specific CAs has been a continuing effort for pursuing ever-improved sensitivity, specificity, and applicability. This is particularly true with magnetic resonance imaging (MRI) due to its intrinsic superb spatial/temporal/contrast resolutions and adequate detectability for tiny amount of substances. In this context, research using small animal tumor models has played an indispensible role in preclinical exploration of tissue specific CAs. Emphasizing more on methodological and practical aspects, this article aims to share our cumulated experiences on how to create tumor models for evaluation and development of new tissue specific MRI CAs and how to apply such models in imaging-based research studies. With the results that are repeatedly confirmed by later clinical applications in cancer patients, some of our early preclinical studies have contributed to the designs of subsequent clinical trials on the new CAs, some studies have predicted new utilities of these CAs; and other studies have led to the discoveries of new tissue- or disease-specific CAs with novel diagnostic or even therapeutic potentials. Among commonly adopted tumor models, the chemically induced and surgically implanted nodules in the liver prove very useful to simulate primary and metastatic intrahepatic tumors, respectively in clinical patients. The methods to create tumor models have eased procedures and yielded high success rates. The specific properties of the new CAs could be outshined by intraindividual comparison to the commercial CAs as nonspecific controls. Meticulous imaging-microangiography-histology matching techniques guaranteed colocalization of the lesion on in vivo MRI and postmortem tissue specimen, hence correct imaging interpretation and longstanding conclusions. As exemplified in the real study cases, the present experimental set-up proves applicable in small animals for imaging-based oncological investigations, and may provide a platform for the currently booming molecular imaging in a multimodality environment.
    Methods 06/2009; DOI:10.1016/j.ymeth.2009.03.014 · 3.22 Impact Factor